Addition of CpG to the Melan-A/MART-1 antigen vaccine improved the weak antigen-specific CD8+ T cell responses that were observed in previous clinical studies of patients with melanoma receiving Melan-A peptide and IFA (13, 91, 92). Here, CD8A is linked to melanoma.